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Disease is often the result of an aberrant or inadequate response to physiologic and pathophysio-
logic stress. Studies over the last 10 years have uncovered a recurring paradigm in which
microRNAs (miRNAs) regulate cellular behavior under these conditions, suggesting an especially
significant role for these small RNAs in pathologic settings. Here, we review emerging principles
of miRNA regulation of stress signaling pathways and apply these concepts to our understanding
of the roles of miRNAs in disease. These discussions further highlight the unique challenges and
opportunities associated with themechanistic dissection of miRNA functions and the development
of miRNA-based therapeutics.Introduction
MicroRNAs (miRNAs) were first discovered in the early 1990s
through the analysis of developmental timing mutants in
C. elegans (Lee et al., 1993; Wightman et al., 1993). It was not
until after 2001, however, that a dedicated field focused on the
study of these regulatory RNAs coalesced, following the identifi-
cation of numerous endogenously expressed small RNAs in
worms, flies, and mammals (Lagos-Quintana et al., 2001; Lau
et al., 2001; Lee and Ambros, 2001). In the ensuing decade,
the study of miRNA biology has attracted remarkable attention,
resulting in rapid advances.We have since learned that mamma-
lian genomes encode 300 conserved miRNA genes, and high-
throughput sequencing studies have identified 1,000 or more
additional loci that produce small RNAs structurally resembling
miRNAs. However, since these additional miRNAs tend to be
poorly conserved and expressed at low levels, their functional
significance is unclear (Chiang et al., 2010; Landgraf et al.,
2007). Small RNA cloning and analysis have also revealed the
presence of other types of silencing RNAs inmammals, including
endogenous short-interfering RNAs (endo-siRNAs) and germ-
line-restricted piwi-interacting RNAs (piRNAs) (Farazi et al.,
2008). Nevertheless, among the varied classes of small RNAs
in mammals, miRNAs appear to have a uniquely important role
in disease phenotypes and we therefore focus our attention on
their functions herein.
In this review, we synthesize our current understanding of the
physiologic roles of miRNAs in mammalian biology and the
manner in which miRNA activities, both normal and aberrant,
contribute to disease. Rather than attempting to present a
comprehensive survey of the numerous studies that have linked
miRNAs to individual disease phenotypes, we emphasize what
appear to be the emerging themes of miRNA function gained
from their evaluation in vivo. Within this context of normal miRNA
biology, we can begin to understand the consequences when
miRNA activities go awry. From recent studies, it has become
apparent thatmiRNAs rarely contribute significantly to the estab-1172 Cell 148, March 16, 2012 ª2012 Elsevier Inc.lishment of the mammalian body plan and the specification of
diverse cell lineages. While at first blush this appears to indicate
a lesser role for miRNAs in mammalian biology compared to
gene products such as developmentally regulated transcription
factors, their extreme evolutionary conservation would appear
to argue otherwise. Accordingly, further study has revealed
that miRNAs often profoundly influence the responses of fully
developed tissues to physiologic and pathophysiologic stress
(Leung andSharp, 2010). This functional niche suggests a central
role formiRNA-regulated networks in disease states, which often
represent an insufficient or aberrant response under conditions
of stress or injury. Moreover, this role dictates that, in contrast
to classic developmental regulators identified through forward
genetic screens, miRNA loss of function may rarely result in
highly penetrant phenotypes in controlled laboratory environ-
ments. Although somewhat ironic given that the foundingmiRNA
lin-4 was discovered by virtue of its strong developmental
phenotype in C. elegans (Lee et al., 1993), an appreciation of
this prominent role for mammalian miRNAs in dictating cellular
responses in fully developed tissues is essential for appropriate
hypothesis generation, since phenotypes resulting from miRNA
deletions may only be revealed in the setting of the appropriate
perturbagen.
To provide a foundation for understanding miRNA functions in
mammalian systems, we review lessons learned from the study
of animals with deletions of individual miRNA-encoding loci.
From these results, we derive a series of models that describe
the roles of miRNAs in stress responses and then apply these
principles to our current understanding of the functions of
miRNAs in normal mammalian physiology and disease. Exam-
ples from neoplastic and cardiovascular pathology are used to
illustrate these concepts since miRNA roles in these settings
have been studied extensively, although abnormal miRNA
function has been linked to many other disease states. Notable
exceptions to these principles, which have important implica-
tions for the miRNA contribution to Mendelian and complex
genetic disease, are also presented. Finally, we conclude by
reviewing the opportunities and obstacles facing translational
efforts to utilize and target miRNAs for disease diagnosis and
treatment.
miRNA Biogenesis and Function
The vast majority of mammalian miRNAs are encoded by RNA
polymerase II-transcribed genes that may be tens of kilobases
in length and are frequently spliced (Kim andKim, 2007). Approx-
imately one-third of knownmiRNAs are embedded within introns
of protein-coding genes and are co-transcribed with the host
gene, allowing for coordinate regulation of miRNA and protein
expression. In some cases, intronic miRNAs have been shown
to modulate the same biological process as the protein encoded
by that gene. This is exemplified by miR-33 family members,
which cooperate with the sterol regulatory element binding
protein (SREBP) genes in which they are embedded to reduce
cholesterol efflux and increase cholesterol biosynthesis (Najafi-
Shoushtari et al., 2010; Rayner et al., 2010). Within miRNA pri-
mary transcripts, 60–80 nucleotide hairpin structures are first
released and then further processed by the sequential activity
of the RNase III-type endonucleases Drosha and Dicer to
produce mature miRNAs of 21–22 nucleotides in length (Kim
et al., 2009). Fully processed miRNAs associate with, and serve
as specificity determinants for, the Argonaute (Ago) family of
proteins within the RNA-induced silencing complex (RISC).
miRNAs direct Ago proteins to target mRNAs by interacting
with sites of imperfect complementarity. Short ‘‘seed’’ se-
quences at the 50 ends of miRNAs (nucleotides 2–8) are most
critical, and in some cases fully sufficient, for target selection.
When directed to mRNAs via these interactions, Ago proteins
perform a still incompletely defined activity that results in accel-
erated turnover and reduced translation of the targeted tran-
script (Bartel, 2009; Djuranovic et al., 2011).
Many different algorithms exist for the bioinformatic prediction
ofmiRNA targets and all generally predict hundreds of targets for
each miRNA (Alexiou et al., 2009). These highly complex target
networks pose a significant challenge to the mechanistic dis-
section of miRNA-mediated phenotypes. The prevailing model
posits that miRNAs function by fine-tuning the expression of
numerous targets. While each target is regulated subtly (typically
less than a 2-fold change in individual target protein abundance
results from gain or loss of miRNA function), the additive effect of
coordinated regulation of a large suite of transcripts is believed
to result in strong phenotypic outputs. Unfortunately, this hy-
pothesis is nearly impossible to test directly since it is not
logistically feasible to simultaneously restore the levels of many
targets to their natural levels in the setting of miRNA gain or
loss of function in vivo. Therefore, any conclusions drawn from
these types of target analyses will be correlative.
On the other hand, some miRNA-mediated functions might be
driven by the strong regulation of one or a few targets. This is
exemplified by the downregulation of the protein-coding gene
lin-14 by the founding miRNA lin-4 in C. elegans, which is
required for the appropriate timing of larval development
(Lee et al., 1993; Wightman et al., 1993). However, such linear
miRNA-regulated pathways have rarely been demonstrated in
mammals. The demonstration that haploinsufficiency of a targetor targets rescues a miRNA deletion phenotype provides the
strongest evidence of the importance of a specific miRNA:target
interaction in vivo. For example, haploinsufficency of the miR-
146a target Stat1 rescues the autoimmune pathology that arises
in miR-146a knockout mice, implicating a central role for this
target in this miRNA deletion phenotype (Lu et al., 2010). How-
ever, published results of this type are scarce, perhaps reflecting
the time consuming nature and expense of generating and
combining loss-of-function alleles in mice or alternatively re-
flecting the true complexity of miRNA-regulated networks. The
challenges associated with linking specific targets to miRNA-
mediated phenotypes underscore the need for new approaches
to uncover the mechanisms underlying miRNA-mediated func-
tions in vivo.
Lessons frommiRNA Loss-of-Function Studies in Model
Organisms
Over the last 10 years, the consequences of loss of function of
numerousmiRNAs in worms, flies, andmice have been reported.
In addition to classic genetic deletion techniques, the ability to
suppress miRNA function using inhibitory antimiRs has facili-
tated functional analyses in cultured cells and animal models
of disease and has provided unique opportunities for therapeutic
modulation of miRNAs, as discussed in detail later in this review.
AntimiRs are chemically modified oligonucleotides containing
antisense sequences against mature miRNAs. A variety of
chemical modifications enhance the stability, cellular uptake,
and efficacy of antimiRs. ‘‘Antagomirs’’ contain a 20-0-methyl
modification of the sugarmoieties and a phosphorothioate back-
bone to prevent nuclease degradation and enhance binding
affinity, as well as a cholesterol moiety at the 30 end to promote
cellular uptake (Kru¨tzfeldt et al., 2005). Antagomirs associate
with target miRNAs in the RISC, preventing their association
with mRNA targets and promoting miRNA degradation (Ameres
et al., 2010). Antisense oligonucleotides containing a locked
nucleic acid (LNA) modification, in which a covalent bridge
connects the 20-oxygen and the 40 carbon of the ribose moiety
of the nucleotide, creating a rigid bicycle, form especially strong
duplexes with target miRNAs and are readily taken up by cells
in vivo and in vitro (Stenvang et al., 2008). LNA-modified oligonu-
cleotides are thought to sequester miRNAs but not to promote
their degradation. Because of the high affinity of LNA-modified
antisense oligonucleotides for their targets, it has been possible
to use short, so-called ‘‘tiny’’ LNAs, to target just the seed
regions of miRNAs, thereby allowing for inhibition of miRNA
families that share homology in this region (Hullinger et al.,
2011; Obad et al., 2011).
Given the high degree of evolutionary conservation of many
miRNAs chosen for loss-of-function studies and the fact that the
first miRNAs, lin-4 and let-7, were discovered through classic
forward genetic screens and result in potent developmental
defects when deleted (Lee et al., 1993; Reinhart et al., 2000), the
expectation was that miRNA deletion or inhibition would fre-
quentlyproduceovert developmental phenotypes.Although there
havebeen important exceptions, this hasnot been the case for the
vast majority of miRNAs. This has been most thoroughly docu-
mented inC. eleganswhere individual deletion of nearly all known
miRNAs has been shown to have little effect on viability orCell 148, March 16, 2012 ª2012 Elsevier Inc. 1173
development (Miska et al., 2007). Similarly, inmice, themajority of
the 25 miRNA knockouts that have been examined thus far do
not exhibit severe defects in embryonic development.
Initially, it seemed likely that redundancy among related
miRNAs might account for the apparent nonessential role for
individual miRNA genes during development. Within all animal
species, numerous miRNAs share common seed sequences
and are on this basis grouped into families. From a bioinformatic
standpoint, miRNAs within a given family should be largely
redundant since they are expected to have highly overlapping
sets of predicted targets. Nevertheless, bona fide intrafamily
redundancy has rarely been documented through loss-of-func-
tion studies in vivo. For example, deletion of multiple or all
members of 16 miRNA families in C. elegans results in overt
phenotypes in only four cases (the let-7, miR-35, miR-51, and
miR-58 families) (Alvarez-Saavedra and Horvitz, 2010). In mice,
the majority of miRNAs that have been knocked out do not
have identifiable paralogs, essentially ruling out a contribution
of intrafamilial redundancy to the absence of developmental
abnormalities in these animals. Thus far, intrafamilial redundancy
in mice has been documented only for the miR-17-92 and
miR-106b-25 clusters, which act together to regulate multiple
aspects of embryonic development (Ventura et al., 2008), miR-
133a-1 and miR-133a-2, which together are required for appro-
priate cardiac and skeletal muscle development (Liu et al., 2008,
2011), and miR-208b and miR-499, which coregulate muscle
fiber type identity (van Rooij et al., 2009). While other examples
of intrafamilial redundancy will undoubtedly be uncovered, this
mechanism is unlikely to be the major cause of the apparent
tolerance of animals to individual miRNA deletion.
Another source of redundancy may come from miRNAs that
do not share seed sequences yet have acquired overlapping
sets of targets. Interestingly, many miRNA deletions in
C. elegans exhibit synthetic phenotypes when combined with
loss of function of argonaute like 1 (alg-1), which globally reduces
miRNA levels (Brenner et al., 2010). These findings are consis-
tent with the hypothesis that reduced activity of unrelated
compensatory miRNAs may sensitize animals to the effects of
individual miRNA deletion. However, it is important to consider
that the global reduction in miRNA pathway activity that occurs
in alg-1 mutant worms results in a broad range of defects and
likely induces a state of organismal stress that may sensitize
animals to individual miRNA loss of function. Indeed, whereas
the majority of miRNA knockout mice analyzed thus far lack
developmental phenotypes, many have been found to exhibit
profoundly abnormal responses to various stress conditions. In
these cases, the absence of a miRNA may enhance or diminish
the organismal response to stress, thereby augmenting or dimin-
ishing a pathologic process. For example, deletion of miR-208a
has no effect on cardiovascular development or baseline func-
tion but abrogates stress-responsive cardiac remodeling (van
Rooij et al., 2007). Deletion of the miR-143/145 cluster does
not influence vasculogenesis but prevents neointima formation
in response to vascular injury (Xin et al., 2009). The endocrine
pancreas develops normally in miR-375/ mice yet these
animals fail to appropriately expand pancreatic b cell mass in
the setting of obesity-induced insulin resistance, resulting in
severe diabetes (Poy et al., 2009). These findings have important1174 Cell 148, March 16, 2012 ª2012 Elsevier Inc.implications for the study of miRNA functions in animals and
the relevance of these functions to various disease states. A
prominent role for miRNAs in stress responses dictates that
many miRNA loss-of-function phenotypes will be difficult to
detect or absent under controlled laboratory conditions. There-
fore, when evaluating the consequences of miRNA deletion,
a battery of stress paradigms should be applied to the tissue
of interest to reveal otherwise undetectable defects. Further-
more, it can be expected that the stressors that reveal robust
miRNA-mediated phenotypes will provide insight into the dis-
ease settings in which a given miRNA plays a prominent role.
Elucidation of the underlying mechanisms through which
miRNAs participate in these responses is likely to provide new
understanding of disease pathophysiology and uncover new
opportunities for therapeutic intervention.
Potential Mechanisms of miRNA Action in Stress
Responsive Pathways
In Figure 1, we provide a conceptual framework for under-
standing the roles of miRNAs in stress response pathways.
Five mechanisms through which miRNAs can influence stress
signaling are proposed and the predicted consequences of
miRNA loss of function on pathway activity are schematized. It
is important to note that these mechanisms are not mutually
exclusive and a single miRNA could potentially act through
several of these modes, depending on the cellular or functional
context. After describing each model below, specific examples
ofmiRNAs that function through thesemechanisms are provided
in the context of cancer and cardiovascular disease in the
sections that follow.
Stress Signal Mediation
The most conceptually simple mechanism through which
amiRNA can influence a stress response is the scenario in which
the miRNA is directly regulated by a signaling pathway and func-
tions as an essential downstream component within the pathway
(Figure 1A). Stress-dependent regulation can involve upregula-
tion or downregulation of miRNA expression with consequent
effects on downstream mRNA targets and cellular responses.
In the absence of such a miRNA, cellular responsiveness to the
pathway is impaired.
Stress Signal Modulation
A miRNA may be expressed constitutively in a cell but may
modulate the response of the cell to a stress stimulus by titrating
a critical component of a signal transduction pathway (Fig-
ure 1B). In the absence of the miRNA, its target is hyperactive,
leading to an excessive or insufficient response, depending
upon whether the mediator is a positive or negative regulator.
Negative Feedback: Signal Resolution
A miRNA may be activated by, and function as a negative regu-
lator of, a signaling pathway (Figure 1C). Under stress condi-
tions, the pathway may be excessively driven thus increasing
the requirement for miRNA-mediated negative feedback to pre-
vent pathologic hyperactivity or to restore homeostasis once
stress resolves.
Positive Feedback: Phenotypic Switching
In this mode of miRNA action, the miRNA is activated by, and
inhibits negative regulators of, the signaling pathway (Figure 1D).
In this capacity, the miRNA would promote the irreversible
Figure 1. Potential Mechanisms through which miRNAs Regulate
Stress Signaling Pathways and the Consequent Effects of miRNA
Deletion on Pathway Activity
A miRNA can perform a stress signal mediation function (A) in which it acts as
a critical intermediate in a signaling pathway or it may act as a stress signal
modulator (B) in which it titrates a signaling intermediate. A miRNA may
participate in a negative (C) or positive (D) feedback loop that serves to
dampen or amplify a signal, respectively. Lastly, a miRNA may target bothactivation of the pathway and thereby the stable switching of the
cellular state under the stress condition, which can be important
for restoring homeostasis but can also contribute to disease.
Buffering: Signal Stability
Given the multiplicity of miRNA targets within complex biological
pathways, a miRNA may function to buffer pathway activity by
simultaneously dampening expression of both positive and
negative regulators (Figure 1E). In this capacity, the miRNA
would prevent stochastic fluctuations in signaling. This model
is similar to the concept of signal robustness previously put
forward by Cohen, Brennecke, and Stark (Cohen et al., 2006).
Under normal conditions or in controlled laboratory environ-
ments, this type of buffering may not be critical to maintain
normal function. However, in stress states, pathways may
need to be transiently activated to a high level thus increasing
the requirement for buffering to avoid run-away pathway activa-
tion or a failure to achieve the appropriate level of activation.
There are documented examples in which gain- and loss-of-
function of a specific miRNA result in similar phenotypes, which
may reflect the perturbation of a buffering function.
MicroRNAs in Cancer
The initial indication that miRNAs play important roles in human
disease came from studies of their functions in cancer cells.
Several factors contributed to an early appreciation of their
significance in this pathologic setting. First, the founding miR-
NAs discovered in the 1990s inC. elegans, lin-4 and let-7, exhibit
loss-of-function phenotypes that evoke some aspects of tumor
biology. In lin-4 and let-7 mutants, specific stem cell lineages
fail to differentiate at the appropriate larval stages, instead reiter-
ating divisions characteristic of earlier stages and undergoing
extra cell divisions in adults (Lee et al., 1993; Reinhart et al.,
2000). miRNAs were subsequently identified in Drosophila that
regulate cell proliferation and apoptosis, further linking these re-
gulatory RNAs to cancer-relevant pathways (Brennecke et al.,
2003; Xu et al., 2003). At the same time, a seminal study byCroce
and colleagues showed that the miR-15a/16-1 cluster is fre-
quently deleted in chronic lymphocytic leukemia (CLL), impli-
cating these miRNAs as tumor suppressors (Calin et al., 2002).
Together, these findings launched nearly a decade of intensive
study of the roles of miRNAs in cancer.
It is now clear, based on hundreds of expression profiling
studies, that tumors ubiquitously exhibit dysregulated miRNA
expression patterns relative to corresponding normal tissue.
Patterns of miRNA expression provide useful information for
tumor classification and prognosis (Calin and Croce, 2006).
Nevertheless, since miRNA expression is in many cases highly
cell-type specific, the results of such profiling studies must be
interpreted cautiously since apparent dysregulation of miRNAs
in cancer cells can be a manifestation of the distinct cell popula-
tions represented in tumors versus normal tissue. This caveat
highlights the critical importance of rigorous functional experi-
ments to directly assess the consequences of miRNA gain andpositive and negative regulators of a pathway (E), thereby buffering pathway
activity from stochastic fluctuation. For each mode of regulation, the conse-
quences of deletion of the miRNA on pathway activity are schematized on the
right.
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loss of function on tumor cell behavior. Large numbers of such
experiments have now been performed using both human
cancer cell lines and genetically engineered mice and in
numerous cases, miRNA activity has been shown to dramatically
influence tumorigenesis. For example, transgenic expression of
miR-155 (Costinean et al., 2006) or miR-21 (Medina et al., 2010)
is sufficient to initiate lymphomagenesis in mice. Likewise,
expression of the miR-17-92 cluster in mouse hematopoietic
progenitor cells accelerates Myc-induced B cell lymphomagen-
esis (He et al., 2005) and deletion of this miRNA locus induces
apoptosis in Myc-driven lymphoma cells in vitro (Mu et al.,
2009). Conversely, systemic delivery of selected miRNAs
including let-7, miR-26a, miR-34a, and miR-143/145 inhibits
tumor progression in vivo (Kota et al., 2009; Pramanik et al.,
2011; Trang et al., 2011). Coupled with the expression data doc-
umenting dysregulation of these miRNAs in various tumor types
and genomic data linking thesemiRNA genes to recurrent ampli-
fications or deletions in cancer cells, the case has convincingly
been made that specific miRNAs act as oncogenes and tumor
suppressors.
The potent effects ofmiRNA gain and loss of function in cancer
cells starkly contrast with the results obtained frommiRNA dele-
tion studies in worms and mice that, as discussed above, rarely
result in overt phenotypes in unstressed animals. Moreover, in
many cases, delivery of anti-tumorigenic miRNAs appears to
selectively affect tumor cell growth and survival while sparing
normal cells from these effects (Kota et al., 2009; Pramanik
et al., 2011; Trang et al., 2011). These findings suggest that
neoplastic transformation represents a state of heightened
sensitivity to miRNA-mediated activity. Why is cancer a setting
where the phenotypic consequences of miRNA dysregulation
are so robust and what distinguishes the activity of miRNAs in
cancer cells from their activity in nontransformed cells? A parsi-
monious explanation is suggested by the observation that the
phenotypic effects of miRNA-mediated regulation are enhanced
under stress conditions. There is, in fact, a growing appreciation
that cancer itself represents a state of cellular stress. Cancer
cells experience chronic stress induced by DNA damage, aneu-
ploidy, widespread protein misfolding and aggregation due to
imbalances in the stoichiometry of protein complex compo-
nents, andmetabolic reprogramming which can fuel accelerated
growth but lead to the accumulation of reactive oxygen species
and other toxic intermediates (Luo et al., 2009). The resulting
dependency on the compensatory activity of stress-induced
signaling pathways, as well as the requirement for sustained
activation of mitogenic and prosurvival signaling arising from
oncogene activation or tumor suppressor loss, distinguishes
cancer cells from nontransformed cells and provides an oppor-
tunity for miRNAs to drive strong and selective phenotypic
outputs in this pathologic setting. In this regard, the five models
of miRNA activity in stress signaling proposed earlier in this
review (Figure 1) provide a useful framework for mechanistically
understanding the consequences of miRNA dysregulation in
cancer.
The integration of miRNAs into signaling pathways that play
crucial roles in cancer cells has been extensively documented.
This signal mediation function (Figure 2A) is perhaps best repre-
sented by members of the miR-34 family, which are important1176 Cell 148, March 16, 2012 ª2012 Elsevier Inc.components of the p53 tumor suppressor network. From the
perspective of cancer biology, p53 may well be the most impor-
tant stress sensor discovered thus far. Upon its activation in the
setting of genotoxic stress or oncogene hyperactivity, p53
directly transactivates the miR-34a and miR-34b/miR-34c tran-
scription units which then are able to mediate some aspects of
the cellular response to p53 activation, including cell-cycle arrest
and apoptosis (Bommer et al., 2007; Chang et al., 2007; He et al.,
2007; Raver-Shapira et al., 2007; Tarasov et al., 2007). Onco-
genic pathways also utilize miRNAs as effectors of their pro-
tumorigenic programs, as exemplified by the induction of the
miR-17-92 cluster by the MYC oncogene (Figure 2A), which
results in enhanced cellular proliferation, survival, and tumor
angiogenesis (Mendell, 2008; O’Donnell et al., 2005). The gain
or loss of these miRNAs therefore enhances or impairs the
activity of these critical pathways in cancer cells.
miRNAs also influence tumor biology through their action as
signal modulators in which they titrate important components
of cancer-relevant pathways. This role is exemplified by the
miR-15a/miR-16-1 cluster, which targets several factors that
promote cell-cycle progression, including CDK6, CARD10, and
CDC27 (Figure 2B) (Linsley et al., 2007). Deletion of these
miRNAs, as is known to occur in hematopoietic and solid malig-
nancies, would therefore be expected to enhance the prolifera-
tive response of cancer cells to a variety of mitogenic stimuli.
Participation in negative and positive feedback loops is
another common mechanism of miRNA action in cancer cells.
This is well illustrated by miR-146a, which is transactivated by
the NF-kB pathway and negatively feeds back on this signaling
cascade by targeting two upstream activators of the pathway,
TRAF6 and IRAK1 (Figure 2C) (Taganov et al., 2006). Deletion
of miR-146a in mice results in basally increased activity
of NF-kB in splenocytes and the consequent development of
NF-kB-dependent myeloid sarcomas (Zhao et al., 2011). The
NF-kB pathway also has been shown to employ a miRNA-medi-
ated positive feedback circuit in some contexts (Figure 2D).
NF-kB was demonstrated to transactivate LIN28B, which en-
codes an RNA binding protein that blocks processing and
accelerates turnover of let-7 precursors (Iliopoulos et al.,
2009). Lin28B-dependent downregulation of let-7 causes upre-
gulation of IL-6, a let-7 target, which further stimulates NF-kB.
Once activated, this circuit enforces a stable conversion to
a transformed state since the continued production of IL-6
activates protumorigenic STAT3 signaling and the downregula-
tion of let-7 de-represses its oncogenic targets that include
MYC, KRAS, and HMGA2. Myc also directly transactivates
LIN28B and thus reduces expression of its negative regulator
let-7 (Chang et al., 2009), constituting an overlapping positive
feedback loop (Figure 2D). Other miRNAs that appear to partic-
ipate in similar positive feedback pathways to stably enforce
oncogenic signaling programs include miR-21, which is acti-
vated by MAPK/ERK signaling and represses negative regula-
tors of this signaling cascade (Hatley et al., 2010), and the
miR-143/145 cluster, which is repressed when its target, Kras
is activated (Kent et al., 2010) (Figure 2D). In these examples,
restoration of normal miRNA activity would reinstate or interrupt
these negative and positive feedback circuits, respectively,
thereby diminishing oncogenic signaling.
Figure 2. miRNAs that Promote or Inhibit Tumorigenesis Provide
Diverse Functions within Oncogenic and Tumor Suppressor
Signaling Pathways
(A) miR-34 family members and the miR-17-92 cluster function as signal
mediators for the p53 and Myc pathways, respectively.
(B) miR-16 negatively regulates multiple components of mitogenic pathways
and thereby provides an inhibitory signal modulation function.
(C) miR-146a is activated by NF-kB signaling and negatively feeds back on the
pathway by repressing upstream activators of NF-kB. In this capacity, miR-
146a restrains excessive NF-kB activity, which can lead to tumorigenesis.
(D) Let-7,miR-21, and themiR-143/145 cluster participate in positive feedback
loops that function to stably enforce cellular transformation programs upon
activation of oncogenes such as NF-kB, KRAS, and MYC.Finally, we consider miRNAs that perform signal-buffering
functions. Through their ability to target both positive and nega-
tive regulators of a pathway, these miRNAs have the potential to
promote or inhibit tumorigenesis in different cellular contexts
depending on which targets are most critical for pathogenesis
of a given tumor type. The miR-26 family appears to conform
to this paradigm (Figure 2E). miR-26a and miR-26b levels are
frequently reduced in hepatocellular carcinoma (HCC) and low
expression of these miRNAs correlates with shorter patient
survival (Ji et al., 2009). In liver cancer cell lines, expression of
miR-26a induces cell-cycle arrest in part through inhibition of
multiple G1 cyclins and delivery of miR-26a to a mouse model
of HCC potently inhibits tumorigenesis (Kota et al., 2009). In
contrast to these findings, which convincingly support a tumor
suppressor role for miR-26 in liver cancer, a protumorigenic
function for this miRNA family has been uncovered in the context
of glioma. miR-26a accelerates PDGF-induced gliomagenesis in
a mouse model, most likely through its ability to directly target
PTEN, a critical tumor suppressor in many types of cancer
(Huse et al., 2009). Additional study is clearly needed to further
characterize the contexts in which miR-26 pro- or antitumori-
genic functions predominate and the full set of targets which
underlie these opposing activities. Nevertheless, this example
highlights the disparate phenotypic outputs that may result
from aberrant miRNA-mediated control of a complex network
of targets composed of positive and negative regulators.
MicroRNAs in Cardiovascular Disease
The cardiovascular system has been an especially rich source of
miRNAs with roles in disease, perhaps reflecting the suscepti-
bility of the heart and blood vessels to injury and the dependence
of mammals on persistent cardiovascular function (Small and
Olson, 2011). miRNA profiling in mouse models of cardiovas-
cular disease and in human biopsies has revealed signature
patterns of miRNAs diagnostic for numerous cardiovascular
disorders including heart failure, cardiomyopathy, myocardial
infarction, atherosclerosis, ischemia, and angiogenesis. Gain-
and loss-of-function studies in mice have also validated the
importance of specific miRNAs in the pathophysiology of many
of these disorders.
As in cancer, numerous miRNAs function as mediators
of pathogenic stress-related signaling pathways in settings of
cardiovascular disease (Figure 3A). For example, cardiac stress
commonly results in fibrosis due to excessive extracellular
matrix (ECM) production and collagen deposition, leading to
stiffening of the ventricular chambers and cardiac arrhythmias
(Hill and Olson, 2008). miR-29 is downregulated under condi-
tions of cardiovascular disease associated with fibrosis and ex-
cessive ECM production (Boon et al., 2011; Cushing et al., 2011;
van Rooij et al., 2008), implicating this miRNA as a repressive
mediator of fibrotic disease (Figure 3A). This miRNA targets a
broad collection of mRNAs encoding multiple collagen isoforms
and other ECM proteins, such that its downregulation during
cardiovascular disease enhances fibrosis. TGF-b signaling in(E) miR-26 can repress both pro-tumorigenic targets (cyclins D2 and E2) and
antitumorigenic targets (PTEN). These opposing activities endow miR-26 with
context-dependent positive or negative effects on tumorigenesis.
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Figure 3. Examples of miRNAs that Function in
Cardiac Stress Signaling Pathways
(A) miR-29 and miR-15 family members act as mediators
of stress signaling pathways that regulate fibrosis and
cardiomyocyte proliferation and survival, respectively.
(B) miR-208a and miR-126 titrate regulators of cardiac
remodeling and angiogenesis and thereby function as
stress signal modulators.
(C) miR-133a directly targets its activator SRF and in this
manner restrains excessive SRF activity in adult car-
diomyocytes, which can lead to heart failure.
(D) miR-21, miR-199a, and the miR-23a/27a/24-2 cluster
participate in positive feedback loops, which serve to
stably activate signaling pathways that lead to pathologic
cardiac remodeling and angiogenesis.
(E) The miR-143/145 cluster targets both positive and
negative regulators of smooth muscle differentiation.
Through this buffering activity, these miRNAs maintain
the characteristic phenotypic plasticity of this cell type,
allowing smooth muscle cells to proliferate in response
to injury.fibroblasts, a key driver of fibrosis, triggers miR-29 downregula-
tion (van Rooij et al., 2008). Due to the ability of miR-29 to impede
excessive ECM production, delivery of this miRNA may repre-1178 Cell 148, March 16, 2012 ª2012 Elsevier Inc.sent an effective therapeutic approach for fibro-
sis in the cardiovascular system and elsewhere.
However, there are settings where miR-29
overexpression appears to be detrimental.
Aneurysms, characterized by ballooning of the
vasculature, arise from a loss of ECM compo-
nents and therefore may be exacerbated by
miR-29 activity. Accordingly, inhibition of miR-
29 with antisense oligonucleotides stimulates
ECMproduction and diminishes aortic dilatation
in the setting of aortic aneurysm in mice (Boon
et al., 2011).
Members of the miR-15/16 family also serve
as important stress signal mediators through
their roles in pathways that regulate cardiomyo-
cyte proliferation and survival in response to
injury (Figure 3A). During neonatal development,
the miR-15 family is upregulated in the heart,
coinciding with irreversible withdrawal of cardi-
omyocytes from the cell cycle and loss of re-
generative potential (Porrello et al., 2011). This
family of miRNAs is further upregulated fol-
lowing myocardial infarction (MI), causing irre-
versible loss of cardiomyocytes and cardiac
dysfunction (Cimmino et al., 2005; Hullinger
et al., 2011; Linsley et al., 2007; van Rooij
et al., 2008). In keeping with a critical role for
these miRNAs in ischemic cardiac pathology,
inhibition of miR-15/16 family members with
LNA-modified oligonucleotides confers protec-
tion against cardiomyocyte apoptosis after MI
in rodents (Hullinger et al., 2011).
miRNAs have also been documented to
perform stress signal modulation functions in
the setting of cardiovascular disease, as illus-trated by miR-208a (Figure 3B). Numerous forms of cardiac
stress, including myocardial infarction, hypertension, and che-
motherapy, result in pathological remodeling of the heart and
consequent loss of pump function, culminating in heart failure,
arrhythmias, and death (Hill and Olson, 2008). A hallmark of heart
disease is a switch from the adult alpha-myosin heavy chain
(a-MHC) isoform to expression of the fetal b-MHC gene, with
concomitant diminution in cardiac function.miR-208a is encoded
by an intron of the a-MHC gene and is expressed specifically in
the heart along with its host gene (Callis et al., 2009; van Rooij
et al., 2007). miR-208a knockout mice are protected from patho-
logic cardiac remodeling under conditions of chronic stress, indi-
cating that miR-208a is required for the stress response which
contributes to many cardiac diseases (Figure 3B). The actions
of miR-208a appear to be mediated by a set of transcriptional
repressor proteins that govern cardiac gene expression in
response to stress. Thrap1/MED13, a component of theMediator
complex, is among the strongest targets ofmiR-208a (Callis et al.,
2009; van Rooij et al., 2007). Upregulation of Thrap1 (and other
targets), as occurs in the absence of miR-208a, is believed to
impose a blockade to activation of downstream stress-respon-
sive genes, including b-MHC. Systemic delivery of miR-208a
inhibitors delays the onset of cardiac dysfunction in hypertensive
rats, confirming the key role of thismiRNA in pathological cardiac
remodeling and suggesting the therapeutic potential ofmiR-208a
inhibitors in heart disease (Montgomery et al., 2011).
Another example of stress signal modulation by a miRNA
is provided by miR-126, an endothelial cell-specific miRNA en-
coded by an intron of the EGFL7 gene (Fish et al., 2008; Kuhnert
et al., 2008; Wang et al., 2008), which encodes an endothelial
growth factor (Figure 3B). miR-126 knockout mice have fragile,
leaky vessels and display impaired angiogenesis in response
to injury and angiogenic signaling (Kuhnert et al., 2008; Wang
et al., 2008). Deletion of miR-126 impairs angiogenic signaling
at least in part due to the consequent upregulation of the miR-
126 targets Spred1 and PIK2R2which function as negative regu-
lators of the pro-angiogenic MAPK/ERK and PI3K/Akt signaling
pathways, respectively.
As in cancer, negative feedback loops involving miRNAs
play important roles in maintenance of cardiovascular function.
A classic example involves the regulation of serum response
factor (SRF), a key transcriptional regulator of cardiomyocyte
growth and differentiation. SRF activates transcription of miR-
133a in cardiomyocytes, and miR-133a, in turn, negatively regu-
lates SRF expression (Chen et al., 2006; Liu et al., 2008)
(Figure 3C). The importance of this negative feedback loop is
demonstrated by the pathologic consequences that result
from deletion of the two miR-133a-encoding loci in mice (miR-
133a-1 and miR-133a-2). Loss of function of these miRNAs
results in lethal structural heart defects in approximately half of
mutant animals (Liu et al., 2008). Those that survive exhibit aber-
rant expression of smooth muscle genes in adult cardiomyo-
cytes and ultimately succumb to dilated cardiomyopathy, which
can be partially attributed to abnormally high SRF activity.
In addition to negative feedback loops, a related mechanism
of stress-signal dampening occurs when a stimulus that leads
to a specific phenotypic response simultaneously induces an
inhibitor of that phenotype. This type of regulation, referred to
as incoherent feed-forward, is represented by the regulation of
angiogenesis by miR-92a. Ischemia is a potent inducer of angio-
genesis that serves to restore blood flow to poorly perfusedtissue sites. Yet ischemia has also been shown to cause the up-
regulation of miR-92a, which functions as a negative regulator of
blood vessel growth. Systemic delivery of antisense oligonucle-
otides directed against miR-92a in a mouse model of hindlimb
ischemia increases blood vessel growth and improves recovery
from ischemic damage (Bonauer et al., 2009). The antiangio-
genic actions of miR-92a have been ascribed to its repression
of a5 integrin, which exerts proangiogenic activity, but undoubt-
edly other targets also contribute to the effects of miR-92a on
angiogenesis. It is noteworthy that miR-92a is encoded by the
miR-17-92 cluster, which encodes miR-17, -18a, -19a, -20a,
-19b and -92a. miR-18 and -19 have been reported to promote
blood vessel growth and tumor angiogenesis through their ability
to downregulate the anti-angiogenic factors thrombospondin-1
(Tsp-1) and connective tissue growth factor (CTGF) (Dews
et al., 2010). Therefore, the ultimate consequence of expression
of this miRNA cluster on angiogenesis is likely dependent on
which of its targets plays a dominant role in a given tissue or
disease context.
Numerous cardiovascular miRNAs establish positive feed-
back loops that influence phenotypic switching during disease
(Figure 3D). Among this class of miRNAs is miR-21, which is up-
regulated by MAPK/ERK signaling in response to cardiac stress
(van Rooij et al., 2006; Patrick et al., 2010; Thum et al., 2008).
miR-21 targets Sprouty2 (Spry2), a negative regulator of the
MAPK/ERK cascade, thereby further enhancing signaling
through this pathway. Systemic delivery of cholesterol-modified
miR-21 antagomirs has been reported to diminish MAPK
signaling in cardiac fibroblasts and thereby completely prevent
and reverse cardiac dysfunction, fibrosis, and hypertrophy in
response to pressure overload (Thum et al., 2008). Surprisingly,
genetic deletion of miR-21 in mice does not diminish heart
disease in response to pressure overload or multiple other
stresses (Patrick et al., 2010). Likewise, inhibition of miR-21
with LNA-modified oligonucleotides does not prevent patholog-
ical cardiac remodeling in response to stress. These disparate
findings may indicate that the therapeutic activity of choles-
terol-modified miR-21 inhibitors is due to selective uptake into
a key cell type or off-target effects of these molecules. Alterna-
tively, these observations raise the possibility that compensatory
mechanismsmay overcome the absence ofmiR-21 in the setting
of chronic genetic deletion.
Cardiac stress also induces the expression of the miR-23a/
27a/24-2 cluster via activation of the NFAT transcription factor
(Lin et al., 2009), which serves as an effector of the calcium-
sensitive phosphatase calcineurin (Molkentin et al., 1998). miR-
23a, in turn, has been shown to repress expression of the
muscle-specific ubiquitin ligase MuRF1, establishing a positive
feedback loop that perpetuates stress-dependent cardiac
hypertrophy (Figure 3D). Knockdown of miR-23a using miRNA
inhibitors confers resistance to cardiac stress and diminishes
hypertrophy through dampening of this positive feedback loop.
Calcineurin/NFAT signaling also induces expression of miR-
199a (da Costa Martins et al., 2010), which negatively regulates
the inhibitory NFAT kinase Dyrk1a, thereby further amplifying
pathogenic signaling in the heart (Figure 3D). Remarkably, inhibi-
tion of miR-199a has been reported not only to prevent cardiac
hypertrophy and fibrosis in response to stress, but also toCell 148, March 16, 2012 ª2012 Elsevier Inc. 1179
reverse these pathological processes through elevation of
Dyrk1a activity (da Costa Martins et al., 2010).
Expression of themiR-23a/27a/24-2 cluster is also induced by
VEGF-MAPK signaling, establishing another positive feedback
loop involving these miRNAs (Cheng et al., 2009; Zhou et al.,
2011). These miRNAs enhance vessel growth by promoting
angiogenic signaling through targeting of the MAPK inhibitors
Spry2 and Sema6A, which restrain angiogenesis (Figure 3D).
These miRNAs have been implicated in pathological angiogen-
esis of the retina, such that their inhibition represents a potential
therapeutic application for this disorder.
Finally, miRNAs have been described that target both positive
and negative regulators of a cardiovascular stress response
and thereby buffer pathway activity. This is exemplified by the
miR-143/145 cluster, which regulates phenotypic switching of
smooth muscle cells (Boettger et al., 2009; Cheng et al., 2009;
Cordes et al., 2009; Xin et al., 2009). Vascular injury and athero-
sclerosis are accompanied by dedifferentiation and excessive
proliferation of vascular smooth muscle cells, causing occlusion
of the vascular lumen. Expression of miR-143/145 is elevated
upon differentiation of smooth muscle cells and is diminished
in injured and atherosclerotic vessels. Restoration of miR-145
expression in injured arteries through adenoviral delivery
impedes smooth muscle proliferation and neointimal growth.
Paradoxically, mice with genetic deletion of miR-143/145 are
similarly resistant to pathological vascular remodeling in re-
sponse to injury (Xin et al., 2009). Thus, both loss and gain of
thesemiRNAs in vivo evoke similar phenotypes. The prodifferen-
tiation and antiproliferative actions of miR-143/145 have been
attributed to negative regulation of genes involved in actin
dynamics, cytoskeletal remodeling, and actin gene regulation.
Among these targets is the transcriptional repressor KLF4, which
inhibits smooth muscle cell differentiation and promotes prolifer-
ation (Figure 3E). Opposing these actions is themyocardin coac-
tivator MRTF-B, which stimulates smooth muscle differentiation,
and is also targeted bymiR-145. AlthoughmiR-143 and 145 have
been reported to be essential for smooth muscle cell differentia-
tion in vitro (Cordes et al., 2009), knockout mice lacking either or
both of these miRNAs are born without obvious vascular abnor-
malities (Xin et al., 2009). However, contractility of the blood
vessels of these mice is compromised, suggesting a subtle shift
toward a less differentiated phenotype (Boettger et al., 2009).
Taken together, the available data support a model whereby
miR-143/145 do not play a major role in the initial differentiation
of smooth muscle cells. Rather, through the balanced regulation
of positive and negative regulators of smooth muscle differenti-
ation and proliferation, this miRNA cluster maintains the pheno-
typic plasticity of this cell type, facilitating an appropriate (and
sometimes pathologic) response to injury.
MicroRNAs in Mendelian and Complex Genetic Disease
The principle that miRNAs function primarily in governing cellular
behavior under stress conditions in fully developed tissues
would suggest a limited role for these transcripts in highly pene-
trant single-gene genetic disorders since these oftenmanifest as
developmental defects in childhood. Moreover, miRNAs repre-
sent a limited sequence space in which to accumulate mutations
as compared to protein-coding genes and therefore phenotypi-1180 Cell 148, March 16, 2012 ª2012 Elsevier Inc.cally relevant miRNA sequence variants would be expected to
occur rarely. Finally, miRNAs and other noncoding RNAs are
less sensitive to certain classes of mutations such as insertion/
deletions (indels) and nonsense mutations. Whereas these types
of variants lead to truncated open-reading frames in mRNAs,
upstream indels would have little bearing on downstream critical
functional sequences in noncoding RNAs. Thus, it is not sur-
prising that few Mendelian disorders have been linked to muta-
tions in miRNAs. Nevertheless, the small number of human
miRNA loss-of-function phenotypes that have been uncovered
are revealing, since they point to miRNAs that perform develop-
mental functions.
The first human Mendelian disorder to be associated with
miRNA loss of function was nonsyndromic autosomal dominant
progressive hearing loss. Linkage analysis of a large family
segregating the phenotype mapped the causative mutation to
7q32 (Mencı´a et al., 2009), which harbors the miR-183/miR-96/
miR-182 cluster. In light of the fact that expression of these
miRNAs is highly enriched in sensory neurons, including the
hair cells of the inner ear (Weston et al., 2006; Xu et al., 2007),
this cluster represented an attractive candidate gene. Indeed,
in the original family as well as in a second family, heterozygous
point mutations in the seed sequence of miR-96 were identified
that segregated with the deafness phenotype and are absent in
control populations. At the same time, the identification of a
mutation in the seed sequence of miR-96 in mice that results in
a highly similar phenotype further bolstered the conclusion that
altered function of this miRNA leads to adult-onset deafness
(Lewis et al., 2009). It is noteworthy that all of the identified muta-
tions occurred at different positions within the miR-96 seed
sequence. Thus, while each creates a distinct new seed resulting
in the potential acquisition of a unique cadre of novel targets,
the similarities in the phenotypes created by each mutation
implicate miR-96 haploinsufficiency, rather than gain-of-func-
tion, as the cause of the disease. Morpholino-mediated inhibition
of miR-96 in zebrafish results in reduced numbers of hair cells,
further supporting a loss-of-function pathogenetic mechanism
(Li et al., 2010a). Finally, detailed analysis of the phenotype in
miR-96 mutant mice demonstrated that the miRNA is not
required for hair cell specification and embryonic development.
Rather, the miRNA is needed for final postnatal maturation of
hair cells, the failure of which leads to their degeneration (Kuhn
et al., 2011; Lewis et al., 2009).
Another recently identified Mendelian disorder caused,
in some cases, by loss of function of a miRNA is Feingold syn-
drome, an autosomal dominant phenotype characterized by
microcephaly, short-stature, specific anomalies of the fingers
and toes, developmental delay, and, less frequently, gastrointes-
tinal atresia (Feingold et al., 1997). In over two-thirds of cases,
the disease is caused by haploinsufficiency of MYCN (van
Bokhoven et al., 2005). One cause of the remaining cases has
now been shown to be heterozygous deletion of the miR-17-92
cluster (de Pontual et al., 2011). Comparative genomic hybridiza-
tion (CGH) revealed the presence of deletions encompassing
miR-17-92 and the first exon of the Glypican-5 (GPC5) gene in
3 unrelated Feingold syndrome patients lackingMYCN deletion.
The critical contribution of the miR-17-92 cluster to the pheno-
type as opposed to GPC5 was demonstrated through analysis
of mice with germline deletion of these miRNAs. miR-17-92+/
mice exhibit key features of Feingold syndrome, including
reduced body size, microcephaly, and the characteristic digital
abnormalities. Given that the miR-17-92 cluster is known to be
transactivated by the Myc family of transcription factors (Bui
and Mendell, 2010), these findings support a role for the miR-
17-92 cluster as a critical downstream effector ofMYCN activity
in skeletal development. Furthermore, it is worth noting that
among all of the miRNA mutant mice analyzed thus far, miR-
17-92 and miR-96 are unique in their manifestation of highly
penetrant developmental phenotypes in heterozygous animals.
This is in keeping with the notion that the rare miRNAs with
essential roles in development are most likely to be those asso-
ciated with Mendelian phenotypes. The sensitivity of these
phenotypes to miRNA halploinsufficiency likely reflects the exis-
tence of key targets whose activity is highly dose-dependent and
whose mRNA concentration is limiting such that they are partic-
ularly sensitive to changes in miRNA levels.
In addition to rare loss-of-function mutations in miRNAs,
single-nucleotide polymorphisms (SNPs) that more subtly influ-
ence miRNA function have been described. In general, SNPs
are underrepresented within miRNA-encoding loci, which is
consistent with negative selection acting on these sequences
(Saunders et al., 2007). Nevertheless, some polymorphic vari-
ants within miRNAs have been associated with human disease
risk, most notably cancer (Ryan et al., 2010). While the majority
of such studies await rigorous replication in large case-control
studies, a promising example is miR-196a-2 which contains
a SNP that has been associated with an elevated risk of
developing lung, breast, liver, and gastric cancer in indepen-
dent studies and may influence processing of the miRNA (Hoff-
man et al., 2009; Li et al., 2010b; Peng et al., 2010; Tian et al.,
2009).
In contrast to miRNA-encoding loci, target sites encompass
a much greater sequence space since each miRNA can poten-
tially target hundreds of transcripts. Therefore functional alter-
ations in these sequences would be expected to be more
numerous. Indeed, 20,000 SNPs in predicted miRNA binding
sites have been cataloged (Bao et al., 2007; Georges et al.,
2006). On the other hand, the gain or loss of a single target within
a complex miRNA-regulated network might be expected to have
more subtle phenotypic effects. Accordingly, while noMendelian
phenotypes have been linked to target site mutations, there is
growing evidence that polymorphic sequence variants in target
sites can contribute to complex genetic phenotypes. This
concept was initially validated through analysis of quantitative
trait loci that influence muscle mass in sheep (Clop et al.,
2006). A variant in the 30 untranslated region (UTR) of Myostatin
(MSTN) that creates a binding site for the muscle-specific
miRNAs miR-1 and miR-206 was found to be highly associated
with sheep muscularity. Since MSTN is a potent negative regu-
lator of muscle mass, gain of miRNA targeting and subsequent
downregulation of this protein provides a plausible explanation
for increased muscle growth in animals harboring this allele.
This mechanism was first translated to human populations
through analysis of Tourette’s syndrome where a mutation in
the 30 UTR of the SLITRK1 gene that creates a binding site for
miR-189 was reported to be associated with the disease (Abel-son et al., 2005). However, subsequent studies failed to replicate
this association and it has therefore remained controversial
(Chou et al., 2007; Deng et al., 2006; Zimprich et al., 2008).
Many further studies have linked miRNA target site polymor-
phisms to a variety of phenotypes including breast cancer,
hypertension, asthma, and Parkinson’s disease (Sethupathy
and Collins, 2008). For the majority of such studies, it remains
to be seen whether the findings will ultimately be reproducible
in independent analyses. However, one notable example
appears to be a SNP that disrupts a predicted binding site for
let-7 in the 30 UTR of the KRAS oncogene. This variant was first
identified by sequencing the KRAS 30 UTR in non-small-cell lung
cancer (NSCLC) samples and found to be enriched in patients in
two independent NSCLC case-control cohorts (Chin et al.,
2008). Further case-control studies showed that the variant
was also associated with ovarian cancer risk (Ratner et al.,
2010) and reduced survival in oral cancer (Christensen et al.,
2009). Despite the reproducibility of this association, questions
remain regarding the mechanism through which this allele influ-
ences cancer risk. In vitro reporter assays suggest that the risk
variant could lead to higher KRAS expression, but this has not
been confirmed in human tissue samples. Moreover, the SNP
is predicted to base pair with the 30 end of let-7, which, according
to most generally accepted targeting rules, would not be ex-
pected to dramatically influence miRNA-mediated regulation.
Finally, it remains possible that this allele is in linkage disequilib-
rium with the true causative variant that is driving the associa-
tions. These caveats underscore the difficulty in establishing
that miRNA target site variants truly modify disease risk by
altering miRNA regulation versus other potential mechanisms.
Ideally, animal models could be constructed to test proposed
mechanisms directly in vivo, yet given the challenges associated
with discerning phenotypes resulting from complete loss of func-
tion of individual miRNAs, it seems unlikely that effects of these
mutations will be easily observable in genetically-engineered
mice.
Lastly, genes that influence miRNA biogenesis or function
represent an additional source of genetic variation that can
potentially influence disease. This concept was convincingly
demonstrated in a series of large genome-wide association
studies designed to uncover variants associated with the age
of onset of menarche, other traits associated with puberty,
and height (Hartge, 2009; Lettre et al., 2008). Five independent
studies, each analyzing over 15,000 individuals, found strong
association signals near the LIN28B gene, a known negative
regulator of let-7 biogenesis. Furthermore, transgenic expres-
sion of LIN28B in mice increased body size and delayed onset
of puberty, strongly supporting the findings in human popula-
tions (Zhu et al., 2010). Consistent with a miRNA-dependent
mechanism underlying these phenotypes, upregulated genes
in tissues from the transgenic animals were enriched for let-7
targets. These studies exemplify the strength of genetic anal-
yses in highly powered case-control studies coupled with
functional validation in robust animal models to convincingly
pinpoint pathways that regulate human phenotypes. More
studies of this nature are needed to further demonstrate a role
for miRNAs and their targets in genetically complex human
disease.Cell 148, March 16, 2012 ª2012 Elsevier Inc. 1181
Extracellular miRNAs as Biomarkers of Disease
A particularly intriguing, but poorly understood, aspect of the
biology of miRNAs is their presence in numerous body fluids,
including serum, plasma, saliva, and amniotic fluid (Cortez
et al., 2011). miRNAs in serum correlate with the presence of
hematologic malignancies and solid tumors and have been
reported to be of value for early detection of various types of
cancer, preceding diagnosis by conventional methods (Boeri
et al., 2011). Circulating miRNAs have also been correlated
with a variety of cardiovascular disorders, including myocardial
infarction, heart failure, and acute coronary syndrome (Di
Stefano et al., 2011; Tijsen et al., 2010). While these studies point
to extracellular miRNAs as potential biomarkers for disease, it
should be pointed out that most studies to date have involved
relatively small numbers of patients, underscoring the need for
larger prospective human studies to more accurately assess
the clinical value of such measurements.
Despite the uncertainty regarding their clinical utility, the exis-
tence of extracellular miRNAs raises interesting questions about
their origins and functions. In order to elucidate the biologic func-
tions of circulating miRNAs, it will be important to define their
sources to determine whether they are released in an uncon-
trolled manner from injured or diseased cells or if they are
secreted in a regulated fashion as a compensatory response of
tissues to stress. Consistent with the latter scenario, in some
cases the profile of secreted miRNAs does not directly reflect
the miRNA composition of the cell, suggesting regulation of
miRNA release or cellular retention (Collino et al., 2010). miRNAs
are secreted from cells within lipoprotein complexes and
small membranous vesicles known as exosomes. Recently, the
majority of miRNAs in plasma were reported to be associated
with Ago2 ribonucleo-protein complexes in a nonvesicular frac-
tion, suggesting that miRNAs are released within functional
miRNA-induced silencing complexes (Arroyo et al., 2011). The
mechanisms that govern selection of miRNAs for incorporation
into different extracellular complexes under conditions where
miRNA release is regulated will be an important area for
future investigation. Once released, it remains to be determined
whether circulating miRNAs in mammals act at a distance in
intertissue communication, perhaps exhibiting hormone-like
actions. Given that miRNAs typically act stoichiometrically
against mRNA targets, it seems unlikely that the low levels of
circulating miRNAs would achieve sufficient concentrations in
distal target tissues to participate in target repression. Neverthe-
less, it remains formally possible that selective uptake or another
yet-to-be characterized mechanism might allow sufficient intra-
cellular accumulation of a circulating miRNA to result in produc-
tive target engagement.
MicroRNAs as Therapeutics
As described in detail throughout this review, a predominant
paradigm that has emerged from miRNA gain- and loss-of-
function studies is that miRNA dysregulation is well-tolerated in
normal tissues yet can profoundly influence the behavior of cells
and tissues experiencing pathologic stress. It follows from this
concept that miRNA inhibition or delivery may provide a highly
potent means to modulate a disease process while avoiding
unwanted toxic effects in normal tissues. This potential for1182 Cell 148, March 16, 2012 ª2012 Elsevier Inc.a wide therapeutic window has stimulated significant effort
to develop miRNA-targeted therapeutics.
As discussed above, miRNAs are readily inhibited by
antisense oligonucleotides and a variety of modifications have
been developed to enhance the specificity, potency, and bio-
availability of these antimiRs. Antisense oligonucleotides with
the LNA modification, ranging from 7 to 20 nucleotides in
length, can be delivered systemically by intravenous, intraperito-
neal, or subcutaneous injection with little or no toxicity (Stenvang
et al., 2008). Thus far, methods for oral delivery have not been
optimized. Upon systemic delivery, the vast majority of inhibitory
LNA oligonucleotide clears through the liver and kidney (Obad
et al., 2011). However, sufficient uptake to achieve therapeutic
efficacy has been reported in the heart, vascular system, and
immune system in rodents.
The most advanced miRNA therapeutic developed to date is
an LNA-modified antimiR directed against miR-122 as a treat-
ment for hepatitis C virus (HCV) infection. miR-122 performs an
incompletely understood function that is essential for HCV repli-
cation and inhibition of this miRNA suppresses viral replication in
experimental model systems (Jopling et al., 2005). Likewise,
subcutaneous delivery of the LNA miR-122 inhibitor effectively
suppresses HCV replication in African green monkeys and is
currently being tested in humans (Elme´n et al., 2008; Lanford
et al., 2010). Results reported thus far for human Phase II studies
have shown dose-dependent, prolonged viral reduction of 2 to 3
logs from baseline in HCV RNA after four weeks of treatment,
without evidence of toxicity.
Not surprisingly, many miRNAs appear to play beneficial
rather than pathologic roles in settings of disease. Thus, the
development of miRNA mimics represents an important thera-
peutic goal. Unlike miRNA inhibitors, the use of injectable, naked
miRNA mimics has remained problematic. Challenges to the
development of such molecules relate, in part, to the necessity
to deliver synthetic RNA duplexes in which one strand, the
‘‘guide,’’ is identical to the miRNA of interest, whereas the com-
plementary strand, or ‘‘passenger,’’ is modified so as to facilitate
stability and cellular uptake. Aside from difficulties in cellular
uptake of double-stranded mimics, the passenger strand has
the potential to counter-productively act as an antimiR. On the
other hand, miRNA mimicry has been successfully achieved in
rodents by packaging synthetic miRNA duplexes within lipid
nanoparticles. Using this approach, systemic delivery of miRNA
mimics has been successfully applied in multiple experimental
tumor models in mice, resulting in tumor suppression without
apparent toxicity in normal tissues (Pramanik et al., 2011; Trang
et al., 2011). Adeno-associated virus (AAV) has also been
demonstrated to represent an efficacious delivery platform for
miRNAs, especially with AAV serotypes that display tropism
toward specific tissues such as the liver (Kota et al., 2009).
Despite the importance of miRNAs in disease, and encour-
aging preliminary studies of antimiRs and miRNA mimics in
animal models, many challenges must be overcome prior to
the full realization of the promise of miRNA-based therapeutics.
Efficient and selective uptake of antimiRs and mimics into
different tissues has not been optimized. Moreover, it is conceiv-
able that miRNAs that promote disease in one tissue might play
protective roles in another, as illustrated by miR-26a, which
suppresses hepatocellular carcinoma (Kota et al., 2009) but
may promote gliomagenesis (Huse et al., 2009). The safe
application of inhibitors or mimics that target or augment the
activity such miRNAs will therefore require methods for tissue-
specific delivery. Accordingly, methods for controlled delivery
of miRNA inhibitors or mimics through ligand- or antibody-
directed targeting are under development. In addition, tradi-
tional drug development necessitates a demonstration of
correlation between target engagement and therapeutic effi-
cacy. In the case of miRNAs, such correlations are difficult to
establish as it is not currently possible to determine the precise
concentration of effective antimiR or miRNA mimic in a tissue.
Oligonucleotides may be sequestered in various intracellular
and extracellular compartments, creating uncertainty with
respect to dose-response relationships. In addition, since
miRNAs act by modestly repressing myriad high and low affinity
targets to evoke their effects, the use of gene expression
changes as a surrogate read-out for miRNA inhibition or hyper-
activity can provide a qualitative, not quantitative, estimation of
miRNA activity. Thus, the development of methods to precisely
measure miRNA activity in clinical samples represents an impor-
tant future goal.
Another challenge relates to the intriguing observation that,
in some cases, short-term chemical inhibition of a miRNA has
been found to result in a beneficial therapeutic response
whereas genetic deletion of the miRNA has no influence on the
disease process. This scenario is exemplified bymiR-21. Admin-
istration of inhibitors that target this miRNA prevent pathologic
cardiac remodeling yet germ-line deletion of miR-21 has no
effect on cardiovascular pathology (Patrick et al., 2010; Thum
et al., 2008). While these disparate outcomes may indicate that
the beneficial effects of miR-21 inhibitors are due to selective
uptake or activity of antimiRs in specific cell types or to off-target
effects, another possibility is that chronic loss of function of the
miRNA results in adaptive responses within the miRNA target
network that compensate for its absence. Such theoretical
effects raise interesting questions regarding the consequences
of acute versus long-term treatments with miRNA inhibitors in
the settings of disease. To date, most studies in animals have
involved miRNA inhibition over relatively short periods of time.
Whether therapeutic efficacy of miRNA inhibitors will decline
with time as target networks compensate for diminished miRNA
activity remains to be determined.
Looking to the Future
The realization that miRNAs play central roles in disease has
provided a new perspective on our understanding of pathophys-
iologic mechanisms and has offered a new therapeutic modality
for disease modification. Moreover, the identification of the
mRNA targets that mediate the actions of miRNAs in disease
pathways can reveal previously unrecognized components of
cellular stress responses that may serve as targets for more
traditional drug development. The ability to modulate miRNA
activity through the systemic delivery of miRNA inhibitors or
mimics without toxicity provides unprecedented opportunities
for intervening in disease processes. While challenges remain
in this regard, the pace of this field suggests that new discoveries
are forthcoming.ACKNOWLEDGMENTS
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